Editor, Ophthalmology Times
Aldeyra Therapeutics receives Special Protocol Assessment Agreement Letter from FDA for ADX-2191
June 26th 2025ADX-2191 is an investigational drug candidate from Aldeyra, for the treatment of primary vitreoretinal lymphoma (PVRL), a rare and potentially fatal cancer currently with no current FDA-approved therapy
Read More
Valorum Biologics to commercialize Formycon’s Eylea Biosimilar FYB203 in US and Canada
June 26th 2025FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema, macular edema following retinal vein occlusion, and visual impairment due to myopic choroidal neovascularization.
Read More
University of Colorado Anschutz Medical Campus Ophthalmology Department receives $40 million gift
June 9th 2025The gift will be used to treat and potentially cure eye diseases such as macular degeneration and glaucoma, increase focus on basic science, and harness artificial intelligence to revolutionize vision care.
Read More
ViGeneron rebrands as VeonGen Therapeutics, announces rare pediatric disease designation for VG801
June 5th 2025VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the full-length ABCA4 gene for Stargardt disease and related retinal disorders.
Read More
ARVO 2025: Retina extracellular vesicles in diabetic retinopathy
Published: June 1st 2025 | Updated: May 31st 2025At ARVO 2025, in Salt Lake City, Utah, Emma Lessieur-Contreras, MD, PhD, talked about her poster on retina extracellular vesicles, and the role that they play on diabetic retinopathy.
Read More
ARVO 2025: 8 year retrospective of DIMS spectacle lens in children
Published: May 31st 2025 | Updated: May 31st 2025At ARVO 2025, in Salt Lake City, Utah, Carly Lam, PhD, MSc, and Tsz Wing Leung, PhD talked about the evaluation of the visual performance of 2 modified DIMS spectacle lens designs.
Read More
ARVO 2025: Shortened, maintained, or extended dosing intervals through 96 weeks in PHOTON
May 30th 2025At ARVO 2025, in Salt Lake City, Utah, Dilsher Dhoot, MD, FASRS, and Mark Barakat, MD, talked about the PHOTON trial, 8 mg versus 2 mg during the matched dosing phase, and outcomes of shortened, maintained, or extended dosing intervals
Read More
FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease
May 29th 2025Alcon’s dry eye candidate acoltremon 0.003% is a first-in-class thermoreceptor agonist, which stimulates corneal sensory nerves to increase natural tear production to treat the signs and symptoms of dry eye disease.
Read More